Would Your Spravato® Documentation PAAS an Audit?
Spravato® is a Schedule III controlled substance intranasal spray used in conjunction with an oral antidepressant for treatment-resistant depression in adults
Entries by Jennifer Ottman, CPhT
Beware: Same Ingredients, Different FDA Indications
Ozempic® is an injectable diabetic medicine used to improve glycemic control in adults for type 2 diabetes management
Self-Audit Series #6: Transfer Prescriptions
Transferred prescriptions are at high risk for audit recoupment. The PBMs are hitting pharmacies on incomplete transferred prescriptions based on missing required elements.
COVID-19 Vaccine Billing Guidance (April Update)
PAAS National® has seen a few COVID-19 vaccine audits since pharmacies began billing and administering within the last few months. This article contains some reminders and updates from our January 2021 Newsline COVID-19 Vaccine Billing Guidance.
PBM Enforcement of Return to Stock Policies
A PBM will recoup a claim in full if a medication is picked up after their required return to stock timeframes listed in the respective provider manuals.
COVID-19 Vaccine: Are You Prepared to Administer?
Healthcare providers will play a key role when a COVID-19 vaccine becomes available.
Foot Bath Prescriptions – MedImpact is Now the Fifth PBM Investigating
PAAS National® has alerted members through several Newsline articles of an increase in audits with Prime Therapeutics®, Caremark®, OptumRx® and Express Scripts® investigating foot bath prescriptions.
Ozempic®– Bill It Right!
Ozempic® is an injectable used to improve glycemic control in adults with type 2 diabetes mellitus and is available as 2 mg in a 1.5 mL (1.34 mg/mL) pre-filled, disposable pen injector.
PBMs Require “Cut Quantity” Documentation
Whenever a pharmacy dispenses a quantity less than what the prescriber ordered, there should be a reason documented for the “cut quantity”.
